Overview

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Japan. The aim of this observational study is to evaluate the long-term safety and efficacy of activated recombinant human factor VII (NovoSeven®) in subjects with congenital FVII deficiency.
Details
Lead Sponsor:
Novo Nordisk A/S